| Nov 7 |
Castle boasts melanoma test’s capacity to reduce unnecessary testing
|
| Nov 7 |
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
|
| Nov 6 |
Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024
|
| Nov 6 |
Castle Biosciences price target raised to $39 from $37 at Baird
|
| Nov 6 |
Castle Biosciences Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 6 |
Castle Biosciences price target raised to $36 from $28 at KeyBanc
|
| Nov 5 |
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
| Nov 5 |
Castle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call Transcript
|
| Nov 4 |
Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates
|
| Nov 4 |
Castle Biosciences GAAP EPS of $0.08 beats by $0.11, revenue of $85.78M beats by $6.79M
|
